[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-346768-105":59,"doc-detail-346768-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","bispecific-antibodies-in-breast-cancer-immunotherapy-mechanisms-advances-and-translational-challenges","Bispecific Antibodies in Breast Cancer Immunotherapy - Mechanisms, Advances, and Translational Challenges","","Breast cancer remains a leading cause of cancer-related mortality despite targeted therapies and immune checkpoint inhibitors, with clinical benefit largely limited to triple-negative disease. Bispecific antibodies (BsAbs) are engineered to engage tumor-associated antigens and immune checkpoints while recruiting CD3+ T lymphocytes, promoting a cytolytic immune synapse and T-cell activation through granzyme/perforin signaling. Design advances and preclinical/early clinical results support antitumor activity as monotherapy or with chemotherapy, targeted agents, and ICIs. Key translational challenges include antigen heterogeneity, CRS mitigation, pharmacodynamic optimization, and delivery to limit systemic toxicity.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/bispecific-antibodies-in-breast-cancer-immunotherapy-mechanisms-advances-and-translational-challenges/346768/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/bispecific-antibodies-in-breast-cancer-immunotherapy-mechanisms-advances-and-translational-challenges/346768.png","ImageObject",300,407,{"name":92,"@type":93},"Ivy","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main goal of bispecific antibodies in breast cancer immunotherapy?","Question",{"text":112,"@type":113},"BsAbs aim to simultaneously recognize tumor-associated antigens and engage immune effector cells, primarily CD3+ T lymphocytes, to enhance anti-tumor immunity and lysis.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Why are immune checkpoint inhibitors mainly effective in triple-negative breast cancer?",{"text":117,"@type":113},"Their clinical efficacy in breast cancer is predominantly restricted to triple-negative disease, highlighting the need for immunotherapeutic approaches with broader applicability.",{"name":119,"@type":110,"acceptedAnswer":120},"What are the major challenges for translating bispecific antibodies into clinical use?",{"text":121,"@type":113},"Major challenges include tumor heterogeneity and temporal variability of antigen expression, mitigation of cytokine release syndrome, pharmacodynamic optimization, and delivery methods that maximize tumor bioavailability while limiting systemic toxicity.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},346768,1790167921,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":56,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},549758252649,"https://ap-avatar.wpscdn.com/avatar/8000253669c5317157?_k=1778319167496531819","Targeted Oncology (2026) 21:147–165  \n[https://doi.org/10.1007/s1](https://doi.org/10.1007/s1) 1523-026-01198-0  \nBispecific Antibodies in Breast Cancer Immunotherapy: Mechanisms, Advances, and Translational Challenges  \nMarianna Rita Brogna1 · Gerardo Ferrara1 · Valeria Varone1 · Angela Montone1 · Adriana Fava1 ·  \nMaria Rosaria Schiano1 · Michele DelSesto1 · Nubia Pizza1 · Annalisa Prota1 · Carmela Barra1 · Francesca Collina1  \nReceived: 7 October 2025 / Accepted: 13 January 2026 / Published online: 4 February 2026 © The Author(s) 2026  \nAbstract  \nBreast cancer remains a leading cause of cancer-related mortality despite advances in targeted therapies and immune checkpoint inhibitors (ICIs) . While ICIs have reshaped therapeutic paradigms in multiple solid tumors, their clinical efficacy in breast cancer is predominantly restricted to triple-negative breast cancer (TNBC), underscoring the necessity for innovative immunotherapeutic modalities with broader applicability. Bispecific antibodies (BsAbs) are engineered molecules capable of simultaneously engaging tumor-associated antigens (TAAs) such as EGFR, EpCAM, Trop-2, CEACAM5, MUC1, and PSMA, in addition to B7-H4, HER2, and PD-L1, alongside immune effector cells, primarily CD3+ T lymphocytes. This dual targeting promotes the formation of a cytolytic immunological synapse, leading to T-cell activation, proliferation, and targeted tumor cell lysis via granzyme/perforin pathways. Advances in BsAb design—including optimization of affinity constants, valency, Fc engineering to modulate effector functions, and molecular formats (e.g. , BiTEs, DARTs, tandemscFvs)—have improved tumor penetration, pharmacokinetics, and reduced off-target toxicity. Preclinical and early-phase clinical data demonstrate robust antitumor activity of BsAbs, both as monotherapy and in synergistic combinations with chemotherapy, targeted agents, or ICIs, potentially overcoming tumor microenvironment-mediated immunosuppression and immune escape mechanisms. Major challenges include heterogeneity and temporal variability of TAA expression, cytokine release syndrome (CRS) mitigation strategies, pharmacodynamic optimization, and delivery methods to maximize tumor bioavailability while limiting systemic toxicity. This review details the molecular mechanisms, preclinical evidence, clinical trial outcomes, and translational challenges for BsAbs in breast cancer, highlighting their transformative potential in expanding immunotherapeutic efficacy beyond current limitations.  \n1 Introduction  \nBreast cancer is a biologically and clinically heterogeneous disease, representing one of the most prevalent malignancies and a leading cause of cancer-related mortality among women worldwide [1]. Classification of breast cancer is primarily based on the expression of estrogen receptors (ER), progesterone receptors (PR), and human epidermal receptor 2 (HER2), which delineates four major molecular subtypes: Luminal A, Luminal B, HER2-enriched, and Triple-Negative Breast Cancer (TNBC) . Each subtype exhibits distinct prognostic features and therapeutic vulnerabilities. Luminal A tumors, typically ER/PR-positive and HER2-negative with low proliferation indices, are generally associated with favorable outcomes and are effectively managed with endocrine therapy. In contrast, Luminal B tumors, though also hormone receptor-positive, display higher proliferative  \nExtended author information available on the last page of the article  \nactivity and may co-express HER2, necessitating more intensive therapeutic strategies including chemotherapy and HER2-targeted agents when appropriate [2] .  \nHER2-enriched tumors, characterized by HER2 overexpression and lack of hormone receptors, are inherently more aggressive but benefit significantly from HER2-directed therapies. TNBC, defined by the absence of ER, PR, and HER2 expression, remains the most aggressive and therapeutically challenging subtype, often relying on chemotherapy due to the abse","cbCaiisY1ZvCkOOZ","https://ap.wps.com/l/cbCaiisY1ZvCkOOZ","pdf",1421843,"English","# Abstract\n# Introduction\n# Key Points\n## Mechanism of Action\n## Development Status\n## Therapeutic Combinations\n## Main Challenges\n## Future Perspectives","[{\"question\":\"What is the main goal of bispecific antibodies in breast cancer immunotherapy?\",\"answer\":\"BsAbs aim to simultaneously recognize tumor-associated antigens and engage immune effector cells, primarily CD3+ T lymphocytes, to enhance anti-tumor immunity and lysis.\"},{\"question\":\"Why are immune checkpoint inhibitors mainly effective in triple-negative breast cancer?\",\"answer\":\"Their clinical efficacy in breast cancer is predominantly restricted to triple-negative disease, highlighting the need for immunotherapeutic approaches with broader applicability.\"},{\"question\":\"What are the major challenges for translating bispecific antibodies into clinical use?\",\"answer\":\"Major challenges include tumor heterogeneity and temporal variability of antigen expression, mitigation of cytokine release syndrome, pharmacodynamic optimization, and delivery methods that maximize tumor bioavailability while limiting systemic toxicity.\"}]","Bispecific Antibodies in Breast Cancer Immunotherapy - Mechanisms, Advances, and Translational Challenges | PDF",1790062669,48,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c7b93423e5a2d1d2b9ebe5d7224105a9.webp",983,1305,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/61a31b14ffa0f5ae0752fa9a80a49395.webp",982,1304,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c286c7b3dc737076fd5e72d16ef359fd.webp",981,1303,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/28e03aa64cad0e52acd851feff286da0.webp",980,1301]